Feedback
Settings

Settings

Goto Application

10,729 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(ZPTBLXKRQACLCR-XVFCMESISA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 1,073
1.WO/2025/133007NOVEL CANCER ANTIGENS AND METHODS
WO - 26.06.2025
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
 Appl.No PCT/EP2024/087738 Applicant ENARA BIO LIMITED Inventor KUNDU, Samit
There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly ovarian cancer, gastrointestinal cancer, pancreatic cancer, prostate cancer, stromal cancer, osteosarcoma, colon cancer, breast cancer, skin cancer, melanoma, esophageal cancer, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESSC), particularly esophageal cancer, or EAC or ESSC.
2.WO/2025/131119CANCER VACCINES AND USES THEREOF
WO - 26.06.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2024/141468 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor HU, Gang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express a cancer antigen (e.g., PRAME). Also provided herein are methods for treating a cancer.
3.WO/2025/133639DUPLEXING METHOD
WO - 26.06.2025
Int.Class B82B 1/00
BPERFORMING OPERATIONS; TRANSPORTING
82NANOTECHNOLOGY
BNANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
1Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
 Appl.No PCT/GB2024/053198 Applicant TOUCHLIGHT IP LIMITED Inventor ROTHWELL, Paul James
The present invention relates to an improvement to cell-free, in vitro processes that involve the generation of single-stranded nucleic acid concatemers, where these concatemers favour folding into secondary structures due to the presence of stretches of self-complementary sequence. Single stranded concatemers may be produced via rolling circle amplification of a template nucleic acid under certain conditions. The self-annealing and folding of these single-stranded concatemers can frustrate the use of these concatemers for further isolation or product production, particularly where it is desired to make double stranded DNA. The present invention addresses this need by providing a simple and elegant way to ensure that the single stranded nucleic acid concatemer can effectively be duplexed, even if it forms complex self-annealed structures.
4.WO/2025/137089CD19-BINDING POLYPEPTIDES, COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR USE THEREOF
WO - 26.06.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2024/060751 Applicant BEAM THERAPEUTICS INC. Inventor LI, Qing
As described below, the present disclosure features polypeptides capable of binding a cluster of differentiation 19 (CD19) antigen and polynucleotides encoding said CD19-binding polypeptides, compositions comprising the same, and methods for use thereof. The disclosure also features lipid nanoparticles comprising the CD19-binding polypeptides and methods for use thereof for delivery of a polynucleotide (e.g., a polynucleotide encoding a chimeric antigen receptor) to a T cell in vivo.
5.WO/2025/132845GALNAC PHOSPHORAMIDITES AND THEIR USES
WO - 26.06.2025
Int.Class C07H 15/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
 Appl.No PCT/EP2024/087484 Applicant SILENCE THERAPEUTICS GMBH Inventor BETHGE, Lucas
The invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine phosphoramidite containing molecules, and more specifically, to variants of N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with said variants of N-Acetylgalactosamine phosphoramidite containing molecules. Further, the invention provides associated methods of producing and using these molecules, in particular, in the field of medicine. More precisely, the N-Acetylgalactosamine derivatives of the present invention bear in the position 6' a protecting group selected from TMTr, DMTr, MMTr, Fmoc, Px, DMPx.
6.WO/2025/137465BASE EDITORS WITH MODIFIED EDITING WINDOWS
WO - 26.06.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2024/061308 Applicant BEAM THERAPEUTICS INC. Inventor LEE, Seung-Joo
Base editors with modified editing windows, such as base editors containing a deaminase domain and a nucleic acid programmable DNA binding protein domain (napDNAbp), where the napDNAbp is modified relative to a reference napDNAbp to alter the base editing window of the base editors relative to a reference base editor containing the deaminase domain and the reference napDNAbp. In some embodiments, the base editing window is shifted and/or expanded relative to the reference base editor.
7.WO/2025/137379METHODS AND COMPOSITIONS FOR STEM CELL DIFFERENTIATION
WO - 26.06.2025
Int.Class C12N 5/071
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
 Appl.No PCT/US2024/061164 Applicant GC THERAPEUTICS, INC. Inventor CABRAL, Katelyn A.
The present disclosure describes methods, kits, compositions, or pharmaceutical comprising engineered cells configured to express one or more transcription factors that promote cellular phenotypes comprising one or more improved liver functions, where such improved liver function is greater than that of a primary hepatocyte or a wild-type hepatocyte.
8.WO/2025/137545METHODS AND COMPOSITIONS FOR INDUCING IMMUNE SYSTEM TOLERANCE
WO - 26.06.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/US2024/061424 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor ALLEVA, David, G.
This disclosure relates to methods and compositions for the delivery of antigens to host cells for the induction of immune system tolerance. Methods and compositions described herein are useful in the treatment of diseases caused by or relating to immune system dysfunction, including but not limited to autoimmune disorders.
9.WO/2025/137275NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME
WO - 26.06.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2024/061026 Applicant MODERNATX, INC. Inventor AZMI, Ishara
The present disclosure provides novel CRISPR-associated (Cas) nucleases, as well as polynucleotides (e.g., DNA and RNA polynucleotides) encoding the same, host cells containing such nucleases and polynucleotides, and methods of using the foregoing compositions to effectuate genome editing.
10.WO/2025/136994MODIFICATIONS OF POLYNUCLEIC ACID MOLECULES AND USES THEREOF
WO - 26.06.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2024/060593 Applicant SIRIUS THERAPEUTICS, INC. Inventor BRADSHAW, Curt W.
Disclosed herein are modifications of polynucleic acid molecules such as inhibitory polynucleic acid molecules and pharmaceutical compositions comprising modified polynucleic acid molecules. Further, provided herein are methods for utilization of modified polynucleic acid molecules as well as methods for suppressing an expression of gene targeted by the modified polynucleic acid molecules.
# -